ADRX logo

ADARx Pharmaceuticals, Inc.

ADRX
Healthcare|Biotechnology|US
$13.23
-0.06 (-0.45%)
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Sep 28, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (8)

Jan 2027
Est. completion
P1Healthy Adult Participants
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503n=44
Nov 2027
Est. completion
P3Hereditary Angioedema
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213n=90
Dec 2027
Est. completion
P1P2Hereditary Angioedema
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
NCT05691361n=53
Mar 2028
Est. completion
P1P2Paroxysmal Nocturnal Hemoglobinuria (PNH)
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312n=50
Jul 2028
Est. completion
P2Immunoglobulin A Nephropathy (IgAN)
Chinese Adults With Kidney Disease
NCT07522099n=30
Dec 2028
Est. completion
P2IgAN
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359n=45
Feb 2030
Est. completion
P2Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269n=240
Jun 2030
Est. completion
P3Hereditary Angioedema (HAE)
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499n=90

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P1
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
NCT06205628

Recent Press Releases

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Oct 1, 2026 · GlobeNewsWire
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
Sep 24, 2026 · GlobeNewsWire

SEC Filings (16)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 5, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Oct 2, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Oct 1, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 28, 2026S-8Employee stock planDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 28, 2026424B4Offering prospectusDocumentIndex
Sep 24, 2026EFFECTDocumentIndex
Sep 24, 2026S-1MEFIPO / offering registrationDocumentIndex
Sep 24, 2026CERTDocumentIndex
Sep 22, 20268-A12BDocumentIndex
Sep 21, 2026S-1/AIPO / offering registrationDocumentIndex
Sep 14, 2026S-1/AIPO / offering registrationDocumentIndex
Sep 4, 2026S-1IPO / offering registrationDocumentIndex
Jul 31, 2026DRS/ADocumentIndex
Jun 22, 2026DRSDocumentIndex